A new standard of care for mantle cell lymphoma?
Mené sur 50 patients atteints d'un lymphome à cellules du manteau récidivant ou réfractaire, cet essai de phase II évalue l'efficacité, du point de vue du pourcentage de patients avec une réponse objective, et la toxicité de l'ajout du rituximab à l'ibrutinib
Mantle cell lymphoma is a rare and aggressive form of non-Hodgkin lymphoma that predominantly affects older individuals. Standard first-line therapy for this disease uses immuno-chemotherapy that in younger patients can be consolidated with an autologous stem cell transplant. Whereas a high proportion of patients have an initial response to these treatments, they invariably relapse, and response to subsequent alternate immuno-chemotherapeutic therapies are poor, with patients often dying from progressive disease.
The Lancet Oncology , commentaire, 2014